Quick Links

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity is approved for AMA PRA Category 1 Credit™.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AbbVie.

Privacy Policy
Terms & Conditions
Executive Board
Faculty Portal
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
Physicians’ Education Resource ®, LLC.
All rights reserved.

5th Annual Miami Lung Cancer Conference®

5th Annual Miami Lung Cancer Conference®

March 10, 2018
3555 South Ocean Drive
Hollywood, FL 33019
Phone: (954) 602-6000


Optimized care for patients with lung cancer continues to rapidly evolve across treatment modalities, including chemotherapeutic, targeted, and immuno-oncology strategies. Returning for its 5th year, the Miami Lung Cancer Conference®, will bring the latest updates and advances in current and emerging approaches in treating lung cancer. This 1-day meeting will allow participants to engage with the fields’ top thought leaders, delving into realistic and complex cases. Miami Lung attendees will leave this program able to evaluate emerging therapies, solve unmet clinical problems, and clarify best practice, all to personalize care for their patients with lung cancer. This year’s program will once again highlight PER’s world renowned Medical Crossfire® format, fueling an increased learning and understanding for health care professionals. See you in Miami!

What you will learn at Miami Lung!

  • Methods employed by experts to treat patients with advanced NSCLC who present without actionable oncogenic drivers
  • The cutting-edge research on angiogenesis inhibition in lung cancer, and how these therapies can be used to personalize care in your patients
  • The latest therapies in EGFR-positive NSCLC, and updated strategies to address acquired resistance to EGFR TKIs
  • The latest data on the benefits of immunotherapy and how combination therapies can circumvent escape mechanisms
  • Optimized sequence and ALK inhibitor selection across lines of therapy in NSCLC, and how to address your patients’ crucial questions

Acknowledgment of Commercial Support

This activity is supported by an educational grant from AbbVie.

Learning Objectives

At the conclusion of this symposium, you should be better prepared to:

  • Discuss evidence-based recommendations regarding tumor tissue testing and its role in therapeutic selection for the patients with NSCLC
  • Assess clinical decision-making necessary along multiple lines of care concerning the use of chemotherapeutic, targeted, and immunooncology strategies in the setting of NSCLC
  • Discuss evolving data sets on immunooncology strategies and their use in lung cancers Describe the role of cytotoxic and antiangiogenic approaches in the management of advanced NSCLC
  • Explain optimized strategies to target oncogenic drivers in frontline settings and beyond disease progression
  • Describe advances and future directions for care in the management of squamous NSCLC, as well as treatment considerations for special populations of patients with lung cancer
  • Integrate personalized approaches to manage challenging cases and real-world clinical scenarios in advanced lung cancer settings

Program Co-Chairs

Heather A. Wakelee, MD
Associate Professor, Medicine (Oncology)
Stanford University Medical Center
Stanford, CA

Julie Brahmer, MD
Interim Director, Sidney Kimmel Comprehensive Cancer Center
Associate Professor of Oncology
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, MD

Become a Member

Forgot Password?
Calendar of Events
Filter By